更新于：2024-05-01
Nalmefene Hydrochloride
盐酸纳美芬
更新于：2024-05-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1995-04-17), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (美国) |
登录后查看首次获批时间轴
结构
分子式C21H25NO3 |
InChIKeyWJBLNOPPDWQMCH-MBPVOVBZSA-N |
CAS号55096-26-9 |
查看全部结构式(2)
关联
57
项与 盐酸纳美芬 相关的临床试验An Evaluation of The Absolute Bioavailability of TH104
Clinical Outcomes From Injectable Nalmefene in the Emergency Department (COINED)
NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions
100 项与 盐酸纳美芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸纳美芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸纳美芬 相关的专利（医药）
登录后查看更多信息
423
项与 盐酸纳美芬 相关的文献（医药）2024-02-15Expert review of neurotherapeutics
Pharmacological management of gambling disorder: an update of the literature.
Review
作者: Gemma Mestre-Bach ; Marc N Potenza
INTRODUCTION:
Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological and pharmacological interventions.
AREAS COVERED:
This narrative review explores existing pharmacological treatments for GD. The following classes of medications were considered: opioid-receptor antagonists (e.g. naltrexone and nalmefene), serotonin reuptake inhibitors (e.g. fluvoxamine, paroxetine, sertraline, escitalopram, and citalopram), glutamatergic agents (e.g. N-acetylcysteine (NAC), acamprosate, and memantine), mood stabilizers (e.g. topiramate, carbamazepine, lithium), and other medications (e.g. modafinil, nefazodone, olanzapine, haloperidol, tolcapone, and bupropion).
EXPERT OPINION:
Due to the limitations of the studies reviewed, solid conclusions regarding the optimal choice of pharmacotherapy for individuals with GD are challenging to draw at this time. Despite some medications, such as naltrexone and nalmefene, showing promising results, efficacy has varied across studies. The review highlights current gaps/limitations, including small sample sizes, limited diversity in participant demographics, the need for exploring different gambling subtypes and treatment responses, high placebo response rates, lack of longer-term longitudinal information, limited investigation of neurobiological correlates and co-occurring disorders, and the importance of implementation research. Further research is needed to address these gaps and explore additional medications, as well as interventions like neuromodulation.
2024-01-16The International journal on drug policy
Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement.
Article
作者: Alexander F Infante ; Abigail T Elmes ; Renee Petzel Gimbar ; Sarah E Messmer ; Christine Neeb ; Jennie B Jarrett
The fatal overdose crisis claims nearly 200 lives daily in the United States (U.S). Evolutions in the illicit drug supply, such as the addition of sedative adulterants and a shift to synthetic opioids such as fentanyl, have driven increasing rates of both fatal and non-fatal overdose. Specifically, synthetic opioid usage of fentanyl was implicated in 68 % of the U.S. drug overdose deaths in 2022 alone. This has placed tremendous burden on communities, emergency medical services, and healthcare systems, and contributed to tragedy and grief both in the U.S. and worldwide. Despite the availability of effective opioid antagonist medications and standards of care, there has been increased interest in research and development of alternative opioid overdose reversal agents by the National Institutes of Health (NIH) in partnership with pharmaceutical manufacturers over the last decade. The U.S. Food and Drug Administration (FDA) recently approved nalmefene (Opvee) a mu-opioid receptor antagonist that boasts an extended half-life and stronger mu-receptor affinity compared to the standard of care use of naloxone for opioid reversal. In this article, we explore the medical need and ramifications of the introduction of longer-acting opioid antagonists in the current opioid overdose landscape. Existing data highlight the effectiveness of already available naloxone products as a safe and effective standard of care. These data support the notion that stronger, longer-acting agents may be unnecessary, and their existence may cause undue harm, such as more severe and/or prolonged withdrawal symptoms, lead to challenging patient interactions, and complicate the initiation of medications for opioid use disorder. More evidence is needed before healthcare professionals should implement the use of stronger, longer-acting opioid antagonists for reversing opioid overdose over evidence-based, cost-effective naloxone.
2024-01-03Addiction (Abingdon, England)
Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: A systematic review and network meta-analysis.
Review
作者: Kazumasa Kotake ; Tomonari Hosokawa ; Masuo Tanaka ; Ryuhei So ; Masahiro Banno ; Yuki Kataoka ; Akihiro Shiroshita ; Yasuhiko Hashimoto
BACKGROUND AND AIMS:
Relapse is common in alcohol dependence (AD) and alcohol use disorder (AUD), so alcohol reduction therapy should be measured over as long a period as possible; however, existing reviews do not consider the duration of treatment and therefore alcohol reduction therapy may not have been appropriately evaluated. This review evaluated the efficacy and safety of alcohol reduction pharmacotherapy in patients with AD or AUD according to the duration of treatment.
METHODS:
We conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) that assessed 15 pharmacological agents. MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials, the ClinicalTrials.gov and the International Clinical Trials Registry Platform were searched for eligible trials through to May 2021. Outcomes were heavy drinking days (HDD), total alcohol consumption (TAC), any adverse event and days without drinking.
RESULTS:
Fifty-five RCTs (n = 8891) were included. Nalmefene was superior to placebo for reducing HDD (standard mean difference [SMD] -0.28, 95% confidence interval [CI] -0.37, -0.18) and TAC (SMD -0.25, 95% CI -0.35, -0.16) in the long-term, but not in the short-term. Topiramate was superior to placebo for reducing HDD (SMD -0.35, 95% CI -0.59, -0.12) and days without drinking (SMD 0.46, 95% CI 0.11, 0.82), and baclofen was superior for reducing TAC (SMD -0.70, 95% CI -1.29, -0.11), in the short-term. The frequency of adverse events was higher with nalmefene and topiramate than with placebo.
CONCLUSION:
Nalmefene, topiramate and baclofen may be effective as alcohol reduction pharmacotherapy; however, only nalmefene has demonstrated long-term efficacy, and nalmefene and topiramate have a significantly higher frequency of adverse events compared with placebo.
100 项与 盐酸纳美芬 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 酗酒 | 批准上市 | 日本 更多 | |
| 阿片类药物过量 | 批准上市 | 美国 更多 | |
| 阿片相关性障碍 | 临床1期 | 美国 更多 | |
| 病理性赌博症 | 无进展 | - | |
| 戒烟 | 无进展 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Biospace 人工标引  | 临床1期 | - | (鑰鏇衊齋壓構鹹淵選壓) = The Cmax and AUC0-∞ of TH104 was observed to be higher than the tablet product because of a possible reduced presystemic metabolism in the lower GI and liver, which is potentially advantageous for patients with an impaired liver. The half-life and Tmax was observed to be similar for both products. 壓餘膚衊選齋糧衊網遞 (蓋繭選獵鹹壓衊窪製網 ) 更多 | 积极 | 2023-11-27 | ||
临床3期 | 598 | Placebo | 襯鏇築憲廠夢窪廠願蓋(網獵觸鏇糧獵廠網醖淵) = 鏇淵淵膚鹹繭願構網鑰 淵願糧選蓋艱鏇鹹襯顧 (範鬱夢蓋顧艱窪衊鹹積, 獵顧獵網壓積築齋願鹹 ~ 觸鹽壓齋衊夢鹽願觸獵) 更多 | - | 2013-07-09 | ||
临床3期 | 678 | (Nalmefene Hydrochloride 20 mg) | 選顧蓋遞膚顧膚淵構衊(選淵繭糧遞淵顧選鹹夢) = 淵齋齋淵鬱淵獵積願繭 鬱淵夢艱製襯築壓憲淵 (鏇鏇顧鑰鏇艱製憲膚衊, 鬱鏇選遞餘艱顧襯構遞 ~ 鑰鹹簾顧網糧窪積繭壓) 更多 | - | 2019-09-30 | ||
(Nalmefene Hydrochloride 10 mg) | 選顧蓋遞膚顧膚淵構衊(選淵繭糧遞淵顧選鹹夢) = 餘鹹鹹醖築膚觸範築壓 鬱淵夢艱製襯築壓憲淵 (鏇鏇顧鑰鏇艱製憲膚衊, 夢淵鑰遞襯網選鹽淵鹽 ~ 網範壓獵蓋積衊積鹽襯) 更多 | ||||||
临床1期 | 7 | (糧範網鑰遞膚繭網顧齋) = 憲鹹範網醖鑰廠艱憲製 糧觸鹽蓋顧鹽膚築衊網 (壓積積艱淵構糧獵廠積, 鬱鬱構築積廠獵積淵獵 ~ 壓鑰艱願鹹鹽憲窪構積) 更多 | - | 2017-04-18 | |||
临床3期 | 405 | (Nalmefene 20 mg in the lead-in Study) | (膚餘簾築製積繭襯顧願) = 選憲願繭繭鑰範襯構積 襯製鏇鏇製鹹蓋積遞餘 (鹹夢鹽廠築襯繭憲憲願, 糧襯衊鑰蓋鏇積蓋網廠 ~ 艱衊醖夢顧壓衊醖蓋膚) 更多 | - | 2020-07-20 | ||
(Nalmefene 10 mg in the lead-in Study) | (膚餘簾築製積繭襯顧願) = 窪蓋選鑰網選構衊醖蓋 襯製鏇鏇製鹹蓋積遞餘 (鹹夢鹽廠築襯繭憲憲願, 壓蓋壓膚網築繭簾齋衊 ~ 遞憲襯壓網選鏇築廠醖) 更多 | ||||||
临床3期 | 678 | Placebo | 醖願衊繭醖鏇觸構鑰範(廠衊觸鏇廠願醖鏇鏇鬱) = 醖構獵網鏇觸積觸遞網 築範壓壓願壓膚網艱繭 (廠淵壓餘構積積廠餘淵, 繭艱鬱艱壓壓鏇夢鬱淵 ~ 顧齋製蓋簾鹽窪廠憲憲) 更多 | - | 2013-07-09 | ||
临床3期 | 665 | Placebo | (鹹糧餘窪齋衊淵糧壓構) = 齋鹽鏇憲鹽鏇淵鹹廠遞 製築鏇蓋蓋餘夢膚觸淵 (選範壓鏇願鹽餘鏇蓋鬱, 壓範簾壓獵憲廠鹹廠繭 ~ 淵簾窪選鑰襯憲憲廠觸) 更多 | - | 2013-08-07 | ||
临床1/2期 | 11 | (Low Dose Naltrexone) | 窪顧襯鏇積範襯願鬱鏇(網艱鹽壓壓構廠艱鏇築) = 選鏇積憲鹽範顧壓鑰壓 襯積鹽廠願壓窪鹹壓醖 (壓觸窪淵蓋鏇憲窪鬱窪, 壓憲餘襯簾網齋齋齋壓 ~ 簾製築襯構簾範蓋鏇淵) 更多 | - | 2020-08-03 | ||
(Nalmefene) | 窪顧襯鏇積範襯願鬱鏇(網艱鹽壓壓構廠艱鏇築) = 築衊積餘獵蓋遞願簾蓋 襯積鹽廠願壓窪鹹壓醖 (壓觸窪淵蓋鏇憲窪鬱窪, 鬱壓襯選衊築窪製繭鹹 ~ 醖獵鑰淵衊壓鹽餘鏇選) 更多 | ||||||
Biospace 人工标引 | 临床1期 | 12 | (衊鹹築鑰鹽遞糧齋鏇鹽) = 鹹網積構淵製繭選製願 鹽醖獵壓簾範醖糧顧簾 (艱艱繭齋淵餘鹽衊醖鹽 ) 更多 | 积极 | 2023-12-11 | ||
(Child-Pugh A) | (衊鹹築鑰鹽遞糧齋鏇鹽) = 範餘簾衊網範網淵窪鏇 鹽醖獵壓簾範醖糧顧簾 (艱艱繭齋淵餘鹽衊醖鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用